Low-dose bacille Calmette–Guérin for non-muscle-invasive bladder cancer: Results of a prospective study

Peer review under responsibility of Arab Association of Urology.

Figures & data

Table 1 Tumour characteristics.

Characteristic	N (%)
Bladder tumour
Primary	37 (100)
Recurrent	0
Tumour number
1	23 (62)
2–7	14 (38)
>7	0
Tumour size, cm
<3	29 (78)
⩾3	8 (22)
Associated CIS	1
Tumour stage
Ta	5 (13)
T1	32 (87)
Tumour grade
G1	0
G2	25 (67)
G3	12 (33)

Table 2 Side-effects reported.

Variable	N (%)
Local effects	20 (54.1)
Bladder irritability	10 (27.0)
Dysuria	3 (8.1)
Microscopic haematuria	7 (18.9)
Systemic effects (fever)	6 (16.2)

Table 3 Characteristics of recurrence in the studied patients.

N	Type of recurrence	Time at recurrence (i.e. tumour-free period), months	Tumour grade	Bilharzial ova discovered
1	With progression	7	G3	Yes
2		12	G3	Yes
3		13	G3	Yes
4		19	G3	No
5	Without progression	19	G3	Yes
6		19	G3	Yes
7		24	G3	Yes
8		25	G2	No
9		25	G2	No
10		24	G2	No
11		30	G2	No
12		31	G2	No
13		35	G2	No
14		35	G2	No

Figure 1 Kaplan–Meier survival curve.